KRAS and neoplasm: Specifically, we highlight the interplay between KRAS signaling, the transcriptional coactivator YES1-associated protein (YAP) and Src family kinases (SFKs) in the pathogenesis of PDAC, including metabolic reprogramming and shaping of the tumor microenvironment.